PrEP for Women: Complete Guide to HIV Prevention

Pre-exposure prophylaxis (PrEP) is a game-changing biomedical HIV prevention tool—a daily pill (or long-acting injection) that reduces HIV acquisition risk by up to 99% when taken as prescribed. PrEP is safe, effective, and recommended for women at substantial risk of HIV. Yet women remain underrepresented in PrEP uptake. This guide covers what women need to know.

How PrEP Works

Oral PrEP (tenofovir disoproxil fumarate/emtricitabine — TDF/FTC, brand name Truvada®; or tenofovir alafenamide/emtricitabine — TAF/FTC, brand name Descovy®) concentrates in genital and rectal tissues, blocking HIV reverse transcriptase and preventing viral establishment after exposure. Daily dosing maintains protective drug levels. On-demand (2-1-1) dosing is not recommended for women—only studied in MSM. Long-acting injectable cabotegravir (Apretude®) every 2 months is now an option.

Who Should Consider PrEP? (CDC/USPSTF Indications for Women)

  • Sexually active women with an HIV-positive partner (especially if not virally suppressed)
  • Women with multiple sexual partners or partner(s) of unknown status in high-prevalence areas
  • Women who inject drugs or have partners who inject drugs
  • Women with recent bacterial STI (gonorrhea, chlamydia, syphilis)
  • Women in serodifferent relationships trying to conceive (PrEP + partner's ART = maximal protection)
  • Transgender women (see specific guidance)
  • Any woman who requests PrEP—clinicians should not deny based on perceived risk alone

Getting PrEP

  1. Find a provider: Primary care, OB/GYN, sexual health clinic, Planned Parenthood, telehealth (e.g., Nurx, Mistr, local health dept).
  2. Baseline testing: HIV test (4th-gen Ag/Ab or NAT), renal function (eGFR), hepatitis B/C, STI panel, pregnancy test.
  3. Counseling: Adherence, side effects, follow-up schedule, condom use for STI prevention (PrEP doesn't prevent other STIs).
  4. Prescription: 90-day supply typical; refills require monitoring.

Side Effects

  • Startup syndrome (first 2–4 weeks): Nausea, diarrhea, headache, fatigue—usually self-limited. Take with food.
  • Renal: TDF can reduce eGFR; monitor q3–6 months. TAF has less renal/bone impact.
  • Bone: TDF causes small BMD decline; reversible. TAF preferred if osteoporosis risk.
  • Weight gain: Modest, more with TAF.

Pregnancy & Breastfeeding

  • Pregnancy: TDF/FTC PrEP is recommended for pregnant women at substantial HIV risk (WHO, CDC, DHHS). Extensive safety data—no increase in birth defects, preterm birth, or infant growth issues. Continue throughout pregnancy/postpartum if risk persists.
  • Breastfeeding: TDF/FTC excreted in breast milk at low levels; infant exposure minimal. Considered compatible with breastfeeding by WHO/CDC. Discuss with provider.

Effectiveness & Adherence

  • Daily oral PrEP: ~99% effective with high adherence (≥4 doses/week for women—cervicovaginal tissue requires higher adherence than rectal).
  • Injectable cabotegravir: 89% more effective than daily oral TDF/FTC in HPTN 084 (cisgender women); no adherence gap.
  • Protection wanes rapidly after stopping—discuss discontinuation with provider.

Cost & Access

Most insurance covers PrEP (ACA preventive service = $0 cost-sharing). Uninsured: Gilead Advancing Access, ViiV Connect, state PrEP assistance programs, community health centers. Generic TDF/FTC available.

PrEP empowers women to take control of their HIV prevention. Talk to a provider—you deserve this option.

Women's Health - Related Articles